- Home
- RIGL vs ESRT Comparison
RIGL vs ESRT Comparison
Compare RIGL & ESRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | ESRT |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.9M | 834.5M |
| IPO Year | 2000 | 2012 |
Fundamental Metrics
Financial Performance| Metric | RIGL | ESRT |
|---|---|---|
| Price | $45.86 | $4.19 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $45.67 | $6.35 |
| AVG Volume (30 Days) | 206.3K | ★ 2.7M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.49% |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | $294,282,000.00 | ★ $768,270,000.00 |
| Revenue This Year | N/A | $4.26 |
| Revenue Next Year | $12.75 | $1.52 |
| P/E Ratio | $34.00 | ★ N/A |
| Revenue Growth | ★ 64.15 | 0.05 |
| 52 Week Low | $24.84 | $4.13 |
| 52 Week High | $52.24 | $8.04 |
Technical Indicators
Market Signals| Indicator | RIGL | ESRT |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 30.72 |
| Support Level | $40.05 | $4.13 |
| Resistance Level | $49.50 | $5.85 |
| Average True Range (ATR) | 1.45 | 0.13 |
| MACD | -0.61 | -0.00 |
| Stochastic Oscillator | 17.89 | 14.41 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About ESRT Empire State Realty Trust Inc.
Empire State Realty Trust Inc is a real estate investment trust (REIT) that owns and operates office, retail, and multifamily properties located in New York City, prominently in Manhattan. Its portfolio includes office and retail space as well as residential units. The company's objective is to maximize cash flow and total returns to its shareholders and to increase the value of the properties. Its reportable segments consist of a real estate segment and an Observatory segment. The majority of revenue is derived from the Real Estate segment, which includes all activities related to the ownership, management, operation, acquisition, redevelopment, repositioning and disposition of its traditional real estate assets.